Cabozantinib Tablets

A drug used alone or with other drugs under the brand name Cabometyx to treat certain types of hepatocellular carcinoma (a type of liver cancer), renal cell carcinoma (a type of kidney cancer), and differentiated thyroid cancer and under the brand name Cometriq to treat certain types of medullary thyroid cancer. Cabozantinib-s-malate is also being studied in the treatment of other types of cancer. It blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib-s-malate is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.

Cabozantinib-s-malate is approved to treat:

• Differentiated thyroid cancer
• Hepatocellular carcinoma
• Medullary thyroid cancer
• Renal cell carcinoma

In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating patients with medullary thyroid cancer. The capsule form was approved in the European Union for the same purpose in 2014. In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer and the same was approved in the European Union in September of that year.